NEXENTIS TECHNOLOGIES INC. Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents of $22.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Change in Cash
us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents · last filed 2026-08-13
- NEXENTIS TECHNOLOGIES INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2026-03-31 was -$4.00K.
- NEXENTIS TECHNOLOGIES INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2025-03-31 was -$9.00K, a 400.00% decline year-over-year.
- NEXENTIS TECHNOLOGIES INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for the quarter ending 2024-03-31 was $3.00K.
- NEXENTIS TECHNOLOGIES INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2025 was -$11.00K.
- NEXENTIS TECHNOLOGIES INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2024 was -$8.00K, a 214.29% decline from fiscal 2023.
- NEXENTIS TECHNOLOGIES INC. effect of exchange rate on cash, cash equivalents, restricted cash and restricted cash equivalents for fiscal 2023 was $7.00K.
| Period end | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 3 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 9 month as first filed | Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $22.00K 10-Q · filed 2026-08-13 | |||||
| 2026-03-31 | -$4.00K 10-Q · filed 2026-05-14 | |||||
| 2025-12-31 | -$11.00K 10-K · filed 2026-03-31 | |||||
| 2025-09-30 | -$27.00K 10-Q · filed 2025-11-13 | |||||
| 2025-06-30 | -$18.00K 10-Q · filed 2026-08-13 | |||||
| 2025-03-31 | -$9.00K 10-Q · filed 2026-05-14 | |||||
| 2024-12-31 | -$8.00K 10-K · filed 2026-03-31 | |||||
| 2024-09-30 | -$6.00K 10-Q · filed 2025-11-13 | -$6.03K 10-Q · filed 2024-11-14 | ||||
| 2024-06-30 | $2.00K 10-Q · filed 2025-08-14 | $2.59K 10-Q · filed 2024-08-14 | ||||
| 2024-03-31 | $3.00K 10-Q · filed 2025-05-15 | |||||
| 2023-12-31 | $7.00K 10-K · filed 2025-03-31 | |||||
| 2023-09-30 | $8.49K 10-Q · filed 2024-11-14 | |||||
| 2023-06-30 | $2.72K 10-Q · filed 2024-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |